Valneva (VLA) Hisse Özeti
Özel bir aşı şirketi olan Valneva SE, karşılanmamış ihtiyaçları olan bulaşıcı hastalıklar için profilaktik aşılar geliştirmekte, üretmekte ve ticarileştirmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 6/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 0/6 |
VLA Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Valneva SE Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | €2.48 |
| 52 Haftanın En Yüksek Seviyesi | €5.42 |
| 52 Haftanın En Düşük Seviyesi | €2.14 |
| Beta | 1.33 |
| 1 Aylık Değişim | 3.90% |
| 3 Aylık Değişim | -47.89% |
| 1 Yıllık Değişim | -10.97% |
| 3 Yıllık Değişim | -54.69% |
| 5 Yıllık Değişim | -76.65% |
| Halka arzdan bu yana değişim | -77.42% |
Son Haberler & Güncellemeler
€5.28: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Valneva SE ( EPA:VLA ) just released its latest first-quarter report and things are not looking great. Statutory...
VLA: Lyme Vaccine Progress And Equity Raise Will Shape Balanced Outlook
Analysts have reduced their price target for Valneva from €3.25 to €2.15, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples. What's in the News Valneva filed a follow on equity offering of €37.03 million, covering 15,893,817 ordinary shares at €2.33 per share with attached warrants, under Regulation S (Key Developments).Recent updates
€5.28: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Valneva SE ( EPA:VLA ) just released its latest first-quarter report and things are not looking great. Statutory...VLA: Lyme Vaccine Progress And Equity Raise Will Shape Balanced Outlook
Analysts have reduced their price target for Valneva from €3.25 to €2.15, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples. What's in the News Valneva filed a follow on equity offering of €37.03 million, covering 15,893,817 ordinary shares at €2.33 per share with attached warrants, under Regulation S (Key Developments).VLA: Lyme Vaccine Progress Will Support Earnings Despite Chikungunya Setback
Analysts have kept their Valneva price target steady at €3.25, citing updated assumptions for discount rate, revenue growth, profit margins and future P/E that broadly support the prior valuation level. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial results for their 6-valent OspA-based Lyme disease vaccine candidate PF-07307405, with efficacy above 70% in reducing confirmed Lyme cases in two pre specified analyses and no safety concerns identified at the time of analysis.VLA: Lyme Vaccine Progress Will Offset Chikungunya Headwinds Over Time
Analysts have raised their Valneva price target from €2.95 to €3.25, citing updated assumptions around revenue growth, profit margins, and a slightly lower future P/E multiple as the main factors behind the change. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial data for their investigational 6 valent OspA based Lyme disease vaccine candidate, with efficacy readings in prespecified analyses and Pfizer planning regulatory submissions after reviewing the results and safety profile (Product related announcement).
VLA: Vaccine Partnerships And Guidance Will Drive Bullish Repricing Potential
Analysts have nudged their price target on Valneva slightly lower to about €6.96 from roughly €6.99, reflecting updated assumptions around discount rates, revenue growth, profit margins and future price-to-earnings levels. What's in the News Elaris FlexCo signed an exclusive global license agreement for Valneva's Clostridioides difficile vaccine candidate VLA84, with plans to use the antigen technology in a next generation program and potential milestone and royalty payments tied to future development, regulatory and commercial outcomes (Key Developments).
VLA: Future Travel Vaccine Franchise And Real World Data Will Drive Reassessment
Analysts have reaffirmed their €10.00 price target for Valneva, with updated assumptions showing a slightly higher discount rate and profit margin, alongside a lower future P/E, suggesting a more balanced view of risk and earnings potential. What's in the News Valneva issued earnings guidance for 2026, expecting total revenues of €155 million to €170 million, with product sales of €145 million to €160 million.VLA: Future Lyme Vaccine Milestones Will Shape Bullish Repricing Potential
Analysts have adjusted their fair value estimate for Valneva from €6.51 to about €6.99. This change reflects updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples.VLA: Chikungunya Safety Setbacks Will Weigh On Long Term Earnings Potential
Analysts have reduced their price target on Valneva from €3.25 to €2.95, citing updated assumptions for revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Valneva and Instituto Butantan launched a Pilot Vaccination Strategy in Brazil using single shot chikungunya vaccine IXCHIQ, aiming for 20% to 40% coverage of adults aged 18 to 59 in ten municipalities as part of post marketing effectiveness and safety studies (Key Developments).VLA: Future Vaccine Pipeline Progress Will Support Higher Market Reassessment
Analysts have lifted their fair value estimate for Valneva from €9.50 to €10.00, pointing to adjusted assumptions around discount rates, revenue growth, profit margins and future P/E as the key drivers of the updated price target. What's in the News Valneva decided to voluntarily withdraw the BLA and IND for its chikungunya vaccine IXCHIQ in the US after the FDA suspended the license in August 2025 and later placed the IND on clinical hold following a newly reported foreign serious adverse event that may be plausibly related to vaccination, while causality has not been determined and no active vaccination studies are ongoing (company announcement).VLA: Chikungunya Commercial Uncertainty Will Undermine Long Term Earnings Potential
Analysts have adjusted their price targets for Valneva, with updated assumptions that include a discount rate of 6.76%, revenue growth of 9.16%, a profit margin of 26.93% and a forward P/E of 13.87x, reflecting a recalibration of expectations around the company’s risk profile and earnings outlook. What's in the News Valneva and Serum Institute of India agreed to discontinue their license deal for the single shot chikungunya vaccine, with Valneva regaining full rights to manage supply and commercialization in endemic high risk countries within the funding framework agreed with CEPI and the European Union (Client Announcements).VLA: Higher Long Term Profit Hopes Will Not Offset Rising Risk
Analysts have trimmed their price target for Valneva from €3.75 to €3.25, reflecting higher perceived risk despite more optimistic long term assumptions for revenue growth and profitability. What's in the News Positive Phase 2 antibody persistence and safety data in 304 children for single shot chikungunya vaccine IXCHIQ, supporting full dose selection and planned Phase 3 development in pediatrics (company announcement) Phase 2 Lyme disease vaccine candidate VLA15 shows strong booster response and favorable safety across age groups, reinforcing partnership with Pfizer ahead of planned 2026 BLA and MAA filings, subject to positive Phase 3 results (company announcement) Strategic reorganization to concentrate French operations in Lyon and close the Nantes site.Subdued Growth No Barrier To Valneva SE (EPA:VLA) With Shares Advancing 29%
Despite an already strong run, Valneva SE ( EPA:VLA ) shares have been powering on, with a gain of 29% in the last...Is Valneva (EPA:VLA) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Rapid Lyme Vaccine Development And Rising Preventative Healthcare Will Shape Future Markets
Valneva's substantial improvement in net profit margin and sharp reduction in future P/E have led to a notable upward revision in the consensus analyst price target from €6.97 to €7.48. What's in the News Health Canada granted marketing authorization for IXCHIQ, Valneva’s single-dose chikungunya vaccine, for individuals aged 12 years and older, supported by robust antibody persistence and safety data.Valneva SE's (EPA:VLA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Valneva SE ( EPA:VLA ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month...Upcoming Lyme Vaccine Data Will Unlock Market Opportunities
Potential success of the Lyme disease vaccine could significantly boost future revenue and earnings through strategic regulatory filings and commercialization milestones.Valneva SE (EPA:VLA) Analysts Just Slashed Next Year's Revenue Estimates By 13%
Market forces rained on the parade of Valneva SE ( EPA:VLA ) shareholders today, when the analysts downgraded their...Valneva SE (EPA:VLA) Stock Catapults 35% Though Its Price And Business Still Lag The Industry
Valneva SE ( EPA:VLA ) shares have had a really impressive month, gaining 35% after a shaky period beforehand. Not all...Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Valneva SE ( EPA:VLA ) share price has dived 25% in the last thirty days...€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Valneva SE ( EPA:VLA ) just released its latest quarterly results and things are looking bullish. Results overall were...Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive
Valneva SE ( EPA:VLA ) shares have had a horrible month, losing 29% after a relatively good period beforehand. For any...Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
It's been a good week for Valneva SE ( EPA:VLA ) shareholders, because the company has just released its latest...Hissedar Getirileri
| VLA | FR Biotechs | FR Pazar | |
|---|---|---|---|
| 7D | 0.08% | 3.4% | 2.0% |
| 1Y | -11.0% | 344.2% | 1.3% |
Getiri vs. Endüstri: VLA geçen yıl % 344.2 oranında getiri sağlayan French Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: VLA geçen yıl % 1.3 oranında getiri sağlayan French Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| VLA volatility | |
|---|---|
| VLA Average Weekly Movement | 13.7% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in FR Market | 10.7% |
| 10% least volatile stocks in FR Market | 2.9% |
İstikrarlı Hisse Senedi Fiyatı: VLA hisse senedi fiyatı, son 3 ayda French piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: VLA 'nin haftalık oynaklığı ( 14% ) geçen yıl boyunca sabit kaldı, ancak hala French hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1998 | 674 | Thomas Lingelbach | valneva.com |
Özel bir aşı şirketi olan Valneva SE, karşılanmamış ihtiyaçları olan bulaşıcı hastalıklar için profilaktik aşılar geliştirmekte, üretmekte ve ticarileştirmektedir. Japon ensefalitine karşı aktif bağışıklama için endike inaktive Vero hücre kültürü türevi Japon ensefaliti aşısı IXIARO; Vibrio kolera veya ısıya dayanıklı toksin üreten enterotoksijenik Escherichia coli bakterisinin neden olduğu ishalin önlenmesi için oral bir aşı olan DUKORAL; ve chikungunya virüsünün neden olduğu hastalığın önlenmesi için tek dozluk, canlı zayıflatılmış bir aşı olan IXCHIQ/ VLA1553'ü sunmaktadır. Şirket ayrıca Lyme hastalığına neden olan Borrelia bakterisine karşı bir aşı adayı olan VLA15'i; Shigella bakterisinin neden olduğu ishalli bir enfeksiyon olan shigellosis'e karşı bir tetravalan biyokonjugat aşı adayı olan S4V2'yi; sivrisinek kaynaklı viral bir hastalık olan Zika virüsünü hedef alan bir aşı adayı olan VLA1601'i geliştirmektedir; VLA1554, insan metapnömovirüsünü hedefleyen bir aşı adayı; VLA84, birincil semptomatik clostridium difficile enfeksiyonunun önlenmesini hedefleyen bir aşı adayı; ve VLA2112, epstein-barr virüsü olan hastaları tedavi etmek için bir aşı adayı.
Valneva SE Temel Bilgiler Özeti
| VLA temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | €469.38m |
| Kazançlar(TTM) | -€138.03m |
| Gelir(TTM) | €156.33m |
VLA aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| VLA gelir tablosu (TTM) | |
|---|---|
| Gelir | €156.33m |
| Gelir Maliyeti | €195.58m |
| Brüt Kâr | -€39.25m |
| Diğer Giderler | €98.79m |
| Kazançlar | -€138.03m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 13, 2026
| Hisse başına kazanç (EPS) | -0.73 |
| Brüt Marj | -25.11% |
| Net Kâr Marjı | -88.30% |
| Borç/Özkaynak Oranı | 237.7% |
VLA uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 04:55 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Valneva SE 15 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Vladimira Urbankova | Erste Group Bank AG |
| Simon Scholes | First Berlin Equity Research GmbH |
| Rajan Sharma | Goldman Sachs |